V940-014: A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)

A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
Principal Investigator
Bhasin, Pooja Gogia
Phase
III (Cancer Prevention)
Age Group
Adult
Applicable Disease Sites
Lung Cancer
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Rachel Harper
Clinical Research Specialist
Phone: +1 304-293-6066
Email:

View on ClinicalTrials.gov

Quick Search

Use the full search for additional searching options.